Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
about
Experiences of establishing an academic early phase clinical trials unit.Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics.Novel tropolones induce the unfolded protein response pathway and apoptosis in multiple myeloma cells.Panobinostat and Multiple Myeloma in 2018.
P2860
Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
Bortezomib, thalidomide, dexam ...... , open-label, phase 1/2 trial.
@en
Bortezomib, thalidomide, dexam ...... , open-label, phase 1/2 trial.
@en-gb
Bortezomib, thalidomide, dexam ...... , open-label, phase 1/2 trial.
@nl
type
label
Bortezomib, thalidomide, dexam ...... , open-label, phase 1/2 trial.
@en
Bortezomib, thalidomide, dexam ...... , open-label, phase 1/2 trial.
@en-gb
Bortezomib, thalidomide, dexam ...... , open-label, phase 1/2 trial.
@nl
prefLabel
Bortezomib, thalidomide, dexam ...... , open-label, phase 1/2 trial.
@en
Bortezomib, thalidomide, dexam ...... , open-label, phase 1/2 trial.
@en-gb
Bortezomib, thalidomide, dexam ...... , open-label, phase 1/2 trial.
@nl
P2093
P921
P6366
P1154
2-s2.0-84997820914
P1476
Bortezomib, thalidomide, dexam ...... , open-label, phase 1/2 trial.
@en
P2093
Andrew Hall
Bhuvan Kishore
Heather Oakervee
Jamie Cavenagh
Louise Flanagan
Matthew Streetly
Myeloma UK Early Phase Clinical Trial Network
Rakesh Popat
P304
P356
10.1016/S2352-3026(16)30165-X
P50
P5530
P577
2016-11-11T00:00:00Z
P6179
1004034330
P6366
2555849466